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Objective: To assess clinical utility of serum Clara cell 16-kDa protein measurements in
relation with staging system for systemic sclerosis associated interstitial lung disease.
Materials and methods: Serum levels of Clara cell 16-kDa protein were determined by ELISA in
28  systemic sclerosis patients and 30 healthy controls, and correlated with staging system
for  systemic sclerosis associated interstitial lung disease in systemic sclerosis patients. Lung
involvement was assessed functionally (body plethysmography, diffusing capacity of the
lung for carbon monoxide) and radiologically (an average disease extent on high resolution
computed tomography of the lungs) in SSc patients.
Results: We  observed statistically signiﬁcant differences in serum Clara cell 16-kDa protein
levels between systemic sclerosis patients and healthy controls only in non-smokers. How-
ever,  serum Clara cell 16-kDa protein concentrations were signiﬁcantly elevated in patients
with high resolution computed tomography extent >20% in comparison to patients with
high resolution computed tomography extent <20% (p = 0.01). They correlated positively with
average disease extent on high resolution computed tomography (p = 0.04), an extent of a
reticular pattern on high resolution computed tomography (p < 0.01), and negatively with a
total lung capacity (p = 0.03) and the results of the 6-min walk test (p < 0.01).
Conclusions: Clara cell 16-kDa protein levels can be considered as a supplemental serumbiomarker for systemic sclerosis associated interstitial lung disease.
©  2015 Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).∗ Corresponding author.
E-mail: anolegaw@wp.pl (A. Olewicz-Gawlik).
ttp://dx.doi.org/10.1016/j.rbre.2015.07.005
255-5021/© 2015 Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
icenses/by-nc-nd/4.0/).
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Níveis  séricos  de  proteína  de  células  de  Clara  de  16  kDa  e
comprometimento  pulmonar  em  pacientes  com  esclerose  sistêmica
Palavras-chave:
CC16
Doenc¸a intersticial pulmonar
Esclerose sistêmica
r  e  s  u  m  o
Objetivo: Avaliar a utilidade clínica das medic¸ões séricas da proteína de células de Clara de
16-kDa em relac¸ão ao sistema de estadiamento para doenc¸a pulmonar intersticial associada
a  esclerose sistêmica.
Materiais e métodos: Foram determinados os níveis séricos de proteína de células de Clara
de  16-kDa por ELISA em 28 pacientes com esclerose siste˛mica e 30 controles saudáveis, e
correlacionados com o sistema de estadiamento para doenc¸ pulmonar intersticial associada
a  esclerose siste˛mica em pacientes com esclerose siste˛mica. O envolvimento pulmonar foi
avaliado funcionalmente (pletismograﬁa corporal, capacidade de difusão de monóxido de
carbono) e radiologicamente (extensão média da doenc¸a na tomograﬁa computadorizada
de  alta resoluc¸ão dos pulmões) em pacientes com esclerose siste˛mica.
Resultados: Foram encontradas diferenc¸as estatisticamente signiﬁcativas nos níveis séricos
de  proteína de células de Clara de 16-kDa entre pacientes com esclerose siste˛mica e con-
troles saudáveis apenas em não tabagistas. No entanto, as concentrac¸ões séricas de proteína
de  células de Clara de 16-kDa eram signiﬁcativamente elevadas em pacientes com extensão
>20% na tomograﬁa computadorizada de alta resoluc¸ão em comparac¸ão a pacientes com
extensão <20% na tomograﬁa computadorizada de alta resoluc¸ão (p = 0,01). Os níveis séricos
de  proteína de células de Clara de 16-kDa se correlacionaram positivamente com a exten-
são média da doenc¸a na tomograﬁa computadorizada de alta resoluc¸ão (p = 0,04) e com a
extensão de padrão reticular na tomograﬁa computadorizada de alta resoluc¸ão (p < 0,01), e
negativamente com a capacidade pulmonar total (p = 0,03) e com os resultados do teste de
caminhada de 6 min (p < 0,01).
Conclusões: Os níveis de proteína de células de Clara de 16-kDa podem ser considerados
como  biomarcadores séricos suplementares para a doenc¸a pulmonar intersticial associada
a  esclerose siste˛mica.
© 2015 Elsevier Editora Ltda. Este e´ um artigo Open Access sob uma licenc¸a CCIntroduction
Systemic sclerosis (SSc) is a chronic, autoimmune connective
tissue disease characterised by vasculopathy, inﬂammation
and progressive ﬁbrosis of the skin and internal organs.
The leading causes of morbidity and mortality in patients
with SSc are two SSc-related pulmonary syndromes: pul-
monary arterial hypertension (SSc-PAH) and interstitial lung
disease (SSc-ILD).1 To assess SSc-ILD, high-resolution com-
puted tomography (HRCT) and pulmonary function tests are
performed. In addition, a few lung-speciﬁc serological mark-
ers of SSc-ILD have been described.2–4 This group includes
Clara cell 16-kDa protein (CC16). It is one of the major
proteins secreted by Clara cells and there is growing evi-
dence on its protective role against pulmonary inﬂammatory
response.5
CC16 is a 15.8-kDa homodimeric protein encoded by a gene
localised to chromosome 11.6 It has potent natural immuno-
suppressive and anti-inﬂammatory properties. CC16 has been
shown to modulate inﬂammatory response, including inhibi-
tion of cytosolic phospholipase A2 activity and interferon- in
vitro.7 Changes in serum CC16 concentrations were observed
in patients with different disorders affecting the lungs, includ-
ing decreased CC16 levels in bronchial asthma and increased
in sarcoidosis and idiopathic pulmonary ﬁbrosis.8,9 They were
also noted after exposure to lung irritants.10 Moreover, theBY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
serum level of CC16 has been found to be an indicator of
active pulmonary ﬁbrosis in SSc patients.11 In regard to this
ﬁnding, in the present study we evaluated serum CC16 levels
and examined their association with SSc-ILD assessment in
patients with SSc.
Materials  and  methods
We recruited for the study 28 consecutive patients with SSc (25
females and 3 males, aged between 24 and 70 years) accord-
ing to the American College of Rheumatology classiﬁcation
criteria.12 All patients were also analysed with the use of 2013
classiﬁcation criteria for SSc.13 Patients were grouped accord-
ing to the 2-cutaneous subset classiﬁcation as having diffuse
cutaneous (dcSSc) or limited cutaneous (lcSSc) form of the dis-
ease on the basis of the extent of their skin involvement.14
Healthy controls (n = 30) were non-smoking volunteers and
were statistically matched by gender and age (18–29, 30–44,
45–54 and 55–70 years of age). The study was approved by the
Institutional Review Board at Poznan University of Medical Sci-
ences and written informed consent was obtained from every
participant. A protocol of the conducted research conforms to
the principles of the World Medical Association’s Declaration
of Helsinki.
Clinical assessment comprised the complete medical his-
tories and physical examinations, which included ulcer
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Table 1 – Clinical, laboratory and radiological
characteristics of systemic sclerosis patients.
Disease duration (months) 51.5 ± 12.1
Modiﬁed Rodnan skin score 13 (17)
Antinuclear antibodies 25 (89.3)
Anti-topoisomerase antibodies 10 (35.7)
Anti-centromere antibodies 15 (53.6)
Erythrocyte sedimentation rate (mm/h) 25 (22)
C-reactive protein (mg/L) 0 (5.4)
C3 complement component (g/L) 1162 (236)
C4 complement component (g/L) 191 (66)
EUSTAR systemic sclerosis activity score 2 (3)
HRCT 15 (25)
Extent of disease, % 10 (15)
Extent of a reticular pattern, % 5 (10)
Extent of ground glass, % 9 (32.1)
Presence of honeycombing 58.4 (16.5)
Total lung capacity (p%) 108.2 (21)
Vital capacity (p%) 98.3 (19.7)
Six-minute walk test, distance (m) 375 (90)
Therapy with cyclophosphamide 9 (32.1)
Therapy with methotrexate 5 (17.9)
Therapy with azathioprine 2 (7.1)
Current smokers 6 (21.4)
HRCT, high resolution computed tomography.
in serum CC16 levels between SSc patients (median 9.9
(7.3) ng/mL) and healthy controls (median 8.4 (3.7) ng/mL)
(Fig. 1), or between dcSSc and lcSSc subgroups. However,
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ssessment and evaluation of skin involvement using mod-
ﬁed Rodnan skin thickness score.15 European League Against
heumatism (EULAR) Scleroderma Trials and Research
EUSTAR) Systemic Sclerosis Activity Score was calculated
or all SSc patients. Disease duration was measured from
he onset of the ﬁrst symptom, other than Raynaud’s
henomenon, consistent with SSc. Pulmonary involvement
as assessed functionally (body plethysmography, diffusing
apacity of the lung for carbon monoxide [DLCO] and the 6-
in  walk test) and radiologically (high resolution computed
omography of the lungs, HRCT) as proposed by Goh et al.16
oreover, HRCT images were also assessed for the following
ndings: the average extent of the disease, the extent of a
eticular pattern, the extent of ground glass appearance and
he presence of honeycombing. All HRCT examinations were
valuated by a radiology expert on HRCT ILD. To describe SSc
atients as ‘without pulmonary function impairment’, three
unctional parameters: total lung capacity (TLC), vital capac-
ty (VC) and DLCO were deﬁned as >80% predicted. Blood
amples from patients were collected at the time of the clin-
cal examination on fasting conditions and obtained sera
ere stored at −70 ◦C before the assays were performed. The
nﬂammatory activity was determined by the erythrocyte sed-
mentation rate (ESR, Westergren), high-sensitivity C-reactive
rotein concentration (CRP, enzyme-linked immunosorbent
ssay (ELISA), BioCheck, USA) and complement components
3 and C4 levels (radial immunoelectrophoresis). The titres
f antinuclear antibodies (ANAs) were assessed by an indi-
ect immunoﬂuorescence assay with two BIOCHIPs per ﬁeld
ontaining HEp-20-10 cells and monkey liver tissue (Euroim-
un, Germany). Antibodies to extractable nuclear antigens
ENA) were determined using blot type test ANA Proﬁle 3
Euroimmun, Germany). Serum concentrations of CC16 were
easured using commercially available ELISA kits (BioVendor,
he Czech Republic) according to the manufacturer’s protocol.
Patients’ demographic data were analysed using descrip-
ive statistics and the data were tested for normal distribution
sing the Kolmogorov–Smirnov test. The results are presented
hroughout the article as the mean ± standard deviation (SD)
or normally distributed data or as the median (interquartile
ange, IQR) for non-normally distributed data. Associations
etween different values were examined using Spearman’s
ank-order correlation analysis. Differences between the
roups were calculated using the Mann–Whitney U test. A
-value less than 0.05 was considered statistically signiﬁ-
ant. All statistical analyses were performed with STATISTICA
ata analysis software system (StatSoft, Inc., 2011, version 10,
ww.statsoft.com).
esults
ut of 28 SSc patients, 11 had dcSSc (9 females and 2 males)
nd 17 had lcSSc (16 females and 1 male). Ten patients (35.7%)
ad a modiﬁed Rodnan skin thickness score of more  than 14
nd 7 (25%) had active disease according to EUSTAR activ-
ty score. One patient (3.6%) had SSc-PAH and none of the
atients had impaired renal function. In 27 patients (96.4%)
ung-function tests showed decreased DLCO, VC was dimin-
shed in 4 patients (14.3%) and TLC in 1 patient (3.6%). ThereData presented as the median (interquartile range),
mean ± standard deviation or as n (%).
was no case of concomitant bronchial asthma or sarcoidosis in
the investigated group. Comparison between dcSSc and lcSSc
revealed no statistically signiﬁcant differences in pulmonary
function tests with regard to percentage of predicted TLC, VC
and DLCO. Signiﬁcant abnormalities on HRCT (ILD extent of
>5%) were observed in 53.6% of the patients and ILD extent
>20% was present in 32.1% of the patients with SSc. There
were no patients with the indeterminate extent of the disease
on HRCT. Further characteristics of the patient group at the
time of examination is shown in Table 1.
We did not observe statistically signiﬁcant differencesMedian
Fig. 1 – Serum CC16 (ng/mL) concentrations in healthy
controls (n = 30) and patients with systemic sclerosis (n = 28).
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Fig. 2 – Serum CC16 (ng/mL) concentrations in non-smoker
patients with systemic sclerosis (n = 22) and in healthy
controls (n = 30).
exclusion of smokers from this analysis revealed signiﬁcantly
increased serum CC16 concentrations in non-smoker SSc
patients in comparison to the controls (median 10.2 (5.8) vs.
8.4 (3.7) ng/mL, p = 0.03) (Fig. 2). In the whole investigated
SSc group CC16 concentrations were also associated with
patients’ age (r = 0.41, p = 0.03) and were signiﬁcantly decreased
in smokers (p = 0.03). Serum levels of CC16 were signiﬁcantly
elevated in patients with HRCT extent >20% in comparison
to patients with HRCT extent <20% (p = 0.01) (Fig. 3). More-
over, CC16 levels signiﬁcantly correlated with HRCT extent
when presented as a continuous variable (r = 0.44, p = 0.04) and
with the extent of reticular pattern (r = 0.61, p < 0.01). With
regard to pulmonary function tests CC16 concentrations were
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Fig. 3 – Serum CC16 (ng/mL) concentrations in systemic
sclerosis patients with HRCT extent <20% and HRCT extent
>20%. 0 1 6;5 6(4):309–313
associated negatively with TLC (r = −0.41, p = 0.03) and with the
result of the 6-min walk test (r = −0.55, p < 0.01). No other statis-
tically signiﬁcant associations were detected between serum
CC16 levels and clinical or laboratory ﬁndings, as shown in
Table 1.
Discussion
The current report focuses on serum levels of CC16 in SSc
patients in relation to staging system of SSc-ILD.
We found statistically signiﬁcant difference in serum CC16
levels only between non-smoker SSc patients and healthy
controls, but not when smoker and non-smoker SSc patients
were analysed together as a whole group. It is consistent
with the results from the previous report, where SSc patients
had higher, but not statistically signiﬁcant, serum levels of
CC16 compared with the levels of healthy controls.11 However,
we cannot exclude a bias caused by a small sample num-
ber of smokers and a relatively low number of all individuals
included to the study.
Further, we did not observe a relationship between CC16
levels and VC, as it was reported by the others.11 The most
probable explanation for these discrepancies is the differ-
ence in treatment (no treatment vs. 57.1% of patients treated
with immunosuppressive drugs in our study). These diver-
gent results can also be inﬂuenced by a small sample size in
the present study. However, we  found that CC16 levels were
signiﬁcantly elevated in SSc patients with average disease
extent on HRCT >20% compared to patients with average dis-
ease extent <20%, and that serum CC16 signiﬁcantly correlated
with the average extent of the disease on HRCT when analysed
as continuous variable. These observations are in agreement
with the ﬁnding that serum CC16 levels in SSc patients with
pulmonary ﬁbrosis were remarkably higher in active vs. inac-
tive lung disease. In the study by Hasegawa et al., diagnosis
of active pulmonary ﬁbrosis was based on the presence of
ground-glass appearance or reticular pattern on HRCT of the
chest and >10% change in VC or >15% change in DLCO within 1
year. As our study was based on the case-control approach, we
could not judge the SSc-ILD activity basing on the same crite-
ria, but our results also indicate CC16 as a marker of SSc-ILD,
as we showed an association of CC16 serum levels with the
extent of reticular pattern on HRCT. This ﬁnding is of particu-
lar clinical importance as in the study by Goh et al.16 mortality
in SSc patients was strongly linked not only to the extent
of disease on HRCT, but also to the extent of the reticular
pattern. Therefore, elevated serum CC16 level can be a can-
didate for a prognostic marker in SSc patients, especially in
non-smokers.
Additionally, in this study we observed decreased CC16
serum concentrations in smoking SSc patients. It is concord-
ant with the previous results, which showed approximately
30% reduction of CC16 levels in smokers.17
To sum up, our data indicate that elevated CC16 concentra-
tions reﬂect the degree of lung damage in the course of SSc as
scored with staging system by Goh et al.16 Further, CC16 level
could be considered as a potential serum prognostic marker
in this group of patients, but to conﬁrm this issue prospective
and longitudinal studies are needed.
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